Intuitive Surgical, Inc. $ISRG Shares Sold by Sei Investments Co.

Sei Investments Co. reduced its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 4.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 633,666 shares of the medical equipment provider’s stock after selling 27,419 shares during the period. Sei Investments Co.’s holdings in Intuitive Surgical were worth $292,096,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Alamar Capital Management LLC purchased a new position in Intuitive Surgical during the first quarter valued at approximately $1,643,000. Davis R M Inc. boosted its position in Intuitive Surgical by 1.7% in the 1st quarter. Davis R M Inc. now owns 56,581 shares of the medical equipment provider’s stock worth $26,083,000 after purchasing an additional 943 shares in the last quarter. Cetera Investment Advisers boosted its position in Intuitive Surgical by 2.8% in the 1st quarter. Cetera Investment Advisers now owns 120,628 shares of the medical equipment provider’s stock worth $55,608,000 after purchasing an additional 3,236 shares in the last quarter. NewEdge Wealth LLC grew its stake in shares of Intuitive Surgical by 21.6% during the 1st quarter. NewEdge Wealth LLC now owns 33,535 shares of the medical equipment provider’s stock worth $15,459,000 after purchasing an additional 5,950 shares during the period. Finally, Wiregrass Investment Management LLC increased its holdings in shares of Intuitive Surgical by 5.3% during the 1st quarter. Wiregrass Investment Management LLC now owns 1,482 shares of the medical equipment provider’s stock valued at $683,000 after purchasing an additional 75 shares in the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Insiders Place Their Bets

In other Intuitive Surgical news, EVP Gary Loeb sold 400 shares of the stock in a transaction that occurred on Wednesday, June 10th. The stock was sold at an average price of $424.14, for a total transaction of $169,656.00. Following the completion of the transaction, the executive vice president owned 5,720 shares of the company’s stock, valued at $2,426,080.80. This represents a 6.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Amy L. Ladd sold 119 shares of the firm’s stock in a transaction that occurred on Wednesday, April 29th. The shares were sold at an average price of $463.50, for a total value of $55,156.50. Following the completion of the transaction, the director owned 120 shares in the company, valued at approximately $55,620. This trade represents a 49.79% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 7,169 shares of company stock worth $3,059,135. Corporate insiders own 0.60% of the company’s stock.

Intuitive Surgical Stock Down 2.7%

ISRG stock opened at $340.69 on Thursday. The stock has a market capitalization of $120.66 billion, a P/E ratio of 39.03, a P/E/G ratio of 2.54 and a beta of 1.46. The firm has a 50-day simple moving average of $410.47 and a 200-day simple moving average of $462.47. Intuitive Surgical, Inc. has a 52 week low of $340.61 and a 52 week high of $603.88.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings results on Thursday, July 16th. The medical equipment provider reported $2.80 earnings per share for the quarter, beating analysts’ consensus estimates of $2.48 by $0.32. Intuitive Surgical had a net margin of 28.45% and a return on equity of 17.09%. The firm had revenue of $2.89 billion for the quarter, compared to analyst estimates of $2.83 billion. During the same period last year, the company posted $1.81 EPS. Intuitive Surgical’s quarterly revenue was up 18.4% compared to the same quarter last year. On average, analysts expect that Intuitive Surgical, Inc. will post 8.84 earnings per share for the current year.

Key Stories Impacting Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Analysts still point to strong procedure growth, recurring revenue from instruments/services, a solid cash position, and new catalysts such as da Vinci 5, Ion lung biopsy, SP, and AI-driven software tools that could support long-term growth. Article title
• Positive Sentiment: Some commentary says margin gains, AI software expansion, and global growth could help Intuitive Surgical maintain its premium valuation despite slower U.S. procedure growth. Article title
• Positive Sentiment: One analysis argued the stock may already be pricing in a slowdown, noting ISRG’s growth rate has recently exceeded what is implied by its valuation, which could appeal to long-term investors. Article title
• Neutral Sentiment: Several recent articles frame the stock as a “strong business, but higher-risk valuation” story, with the company still growing but facing margin pressure from tariffs, product mix shifts, and softer demand in some areas. Article title
• Neutral Sentiment: Intuitive Surgical’s latest earnings were described as impressive, which helps support the bull case, but the market has already shifted to debating whether the stock can sustain its premium after the report. Article title
• Negative Sentiment: Analysts have trimmed fair value estimates and price targets, citing a reset in expectations tied to slower procedure growth, Affordable Care Act-related volume uncertainty, and lower MedTech valuation multiples. Article title
• Negative Sentiment: Competitive pressure is also building after Johnson & Johnson received U.S. authorization for its robotic surgery device, adding another rival in a market long dominated by ISRG’s da Vinci system. Article title
• Negative Sentiment: Multiple reports note the stock has fallen sharply this year and recently hit a new 1-year low after an analyst downgrade, underscoring continued investor concern over valuation and near-term growth. Article title

Analysts Set New Price Targets

Several research firms recently issued reports on ISRG. Robert W. Baird decreased their target price on shares of Intuitive Surgical from $525.00 to $500.00 and set an “outperform” rating for the company in a research note on Friday, July 17th. Wells Fargo & Company restated an “overweight” rating and set a $487.00 price target (down from $654.00) on shares of Intuitive Surgical in a research report on Friday, July 17th. Raymond James Financial reaffirmed an “outperform” rating and issued a $483.00 price objective (down from $577.00) on shares of Intuitive Surgical in a report on Friday, July 17th. Bank of America lowered their target price on shares of Intuitive Surgical from $520.00 to $515.00 in a research note on Friday, June 12th. Finally, Mizuho set a $500.00 target price on Intuitive Surgical and gave the company a “neutral” rating in a research report on Wednesday, July 15th. Twenty-one analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Intuitive Surgical currently has an average rating of “Moderate Buy” and an average target price of $523.46.

Intuitive Surgical Company Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.